Plain-English translation of NCT06825559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a medication called Saroglitazar Magnesium in people who have moderate liver cirrhosis due to cholestatic liver disease. Researchers want to understand how this medication moves through the body, how safe it is, and how well patients tolerate it. The study will enroll 6 participants who will take the medication every other day for about a month.
Cholestatic liver disease is a serious condition where bile cannot flow properly through the liver, leading to cirrhosis and liver damage. This trial exists to explore whether this medication might help treat this condition and to make sure it is safe for people whose livers are already significantly damaged.
You likely qualify if…
You likely don't qualify if…
You will take one 1 mg tablet of the medication by mouth every other day in the morning before breakfast for 29 days. During the study, you will have clinic visits where researchers will check your blood work, monitor your health, and ask how you are feeling. The study is designed to be relatively short and focused on understanding how your body handles this new medication and whether you experience any side effects.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Zydus Therapeutics Inc.
Enrollment target
~6 participants
Started
August 2025
Primary completion
December 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Farheen Shaikh
Zydus Therapeutics Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.